A frank review of the natural compounds and metabolic strategies that have real evidence in glioblastoma - and the ones that do not. Everything here is discussed as an adjunct to standard treatment, never as a replacement.
Jump to what matters most to you right now:
Every entry below is tagged with an evidence label. "Human RCT" means there is at least one randomised human trial in a brain tumour or closely-related setting. "Small human trials" means published human studies exist but are underpowered or single-arm. "Preclinical + case series" means the mechanism is documented in cells or mice, and a small number of patient reports exist. "Preclinical only" means there is no meaningful human data yet - the science is interesting but the case is not made.
Nothing here treats or cures glioblastoma. Standard treatment - maximal safe resection, chemoradiation with temozolomide, adjuvant temozolomide, and where appropriate TTFields - remains the backbone. Everything on this page is discussed as an adjunct: to help you tolerate treatment better, to target specific side effects, or to add pressure to the same pathways your oncology plan is already working on. Nothing here should be started without your treating team seeing your full medication list first.
This is the strongest single natural-adjunct case in glioma. Boswellia serrata is an Ayurvedic resin extract; its active boswellic acids are 5-lipoxygenase inhibitors, and they appear to reduce peritumoral oedema in brain tumour patients.
Kirste et al. (Cancer, 2011) randomised 44 patients receiving radiotherapy for brain tumours to either 4,200 mg/day Boswellia extract or placebo. Roughly 60% of the Boswellia group had >75% reduction of peritumoral oedema on MRI, versus 26% in the placebo group. Multiple smaller case series and observational reports support the signal.
Studied doses run 900-4,200 mg/day of standardised extract (65-70% boswellic acids). Common practice is 1,200-2,400 mg/day divided in 2-3 doses, taken with food. Side effects are usually mild - reflux, loose stools - and it is generally well-tolerated alongside dexamethasone tapers.
Steroid-sparing potential is the practical use
The clinical value most patients get from Boswellia is help tapering dexamethasone. Dexamethasone works but its long-term side effect load - muscle loss, mood, blood sugar, sleep, infection risk - is significant. Boswellia is one of the few adjuncts that can genuinely help lower the steroid dose sooner. Do the taper with your neuro-oncologist, not on your own.
Curcumin is the most-studied natural compound in glioma preclinical models. It hits multiple pathways relevant to GBM - NF-kB, STAT3, PI3K/Akt, and the stem-cell state. The problem has always been getting a meaningful dose past the blood-brain barrier.
Plain turmeric powder from a kitchen shelf will not reach a therapeutic level in the brain. Enhanced formulations exist - Meriva/phytosome, Theracurmin, Longvida, liposomal - and demonstrate 10-30x higher absorption in pharmacokinetic studies. If you are considering curcumin as an adjunct, use one of these; otherwise the discussion is academic.
Preclinical work suggests curcumin can chemosensitise glioma cells to TMZ. Human data during active TMZ chemotherapy is limited to case reports and small series. A cautious practice pattern: pause high-dose curcumin during the six-week concurrent chemoradiation phase, reintroduce during maintenance. A less conservative practice: use an enhanced-absorption formulation throughout, at standard supplemental doses. Discuss with your neuro-oncologist.
Three species come up repeatedly in integrative oncology practice. The evidence base is stronger for their immune-modulating role than for direct anti-glioma activity.
Approved as an adjuvant cancer therapy in Japan for gastric and colorectal cancer since the 1980s. In glioma the evidence is indirect - immune modulation matters more once checkpoint inhibitors or personalised vaccines are in play. Not a stand-alone anti-glioma agent, but a reasonable adjunct during immunotherapy or trial participation.
The most interesting mushroom for brain tumour patients because it stimulates nerve growth factor. Small studies suggest a benefit for cognitive symptoms, which is relevant during and after cranial radiation. Preclinical anti-glioma data exists but has not been replicated in humans. Best case: reduce the cognitive tax of treatment, not treat the tumour.
Immune-modulating, well-tolerated. Some evidence for reducing chemotherapy-related fatigue and improving quality of life. Not glioma-specific. A reasonable inclusion in a general integrative programme; not a targeted GBM strategy.
Lissoni's group in Milan ran a series of trials in the 1990s and 2000s, including one specifically in glioma patients receiving radiotherapy. The 1996 trial randomised 30 GBM patients to radiotherapy alone versus radiotherapy plus 20 mg melatonin nightly; the melatonin arm showed higher one-year survival (six of fourteen versus one of sixteen). The trial is small, single-centre, and dated, but the signal has held up in later work and mechanistically melatonin is antioxidant, circadian-restorative, and appears to sensitise glioma cells to radiation.
Practical dose range studied: 10-40 mg nightly at bedtime. This is substantially higher than the 0.3-3 mg used for sleep; discuss with your oncologist. Melatonin is well-tolerated but can potentiate sedatives and blood pressure medications.
Glioma cells are unusually dependent on glucose. Ketones bypass that route. This is the mechanism behind ketogenic-metabolic therapy in GBM. The evidence includes multiple small feasibility studies, case series with unusually long survivors, and now several phase 1/2 trials in progress.
The compounds and strategies most often discussed in an adjunctive protocol: MCT oil for reliable ketone production, exogenous ketone esters or salts to smooth the transition, alpha-lipoic acid and hydroxycitrate as metabolic co-agents, and time-restricted eating or short fasting-mimicking cycles around chemotherapy. All of this belongs in a supervised programme with blood-ketone and glucose monitoring - not a self-managed protocol.
We treat the metabolic strategy as a full workstream on its own - not something to sprinkle on top of standard care. See our Glucose-Ketone Index (GKI) page for the mechanism, monitoring targets, and how it fits into the overall treatment plan.
A frequently asked question: is it safe to take antioxidants (vitamin C, vitamin E, N-acetylcysteine, high-dose glutathione) during radiation and temozolomide? Radiation and alkylating chemotherapy work partly by generating oxidative damage to tumour cells; the concern is that high-dose antioxidants could theoretically blunt that mechanism.
The evidence is mixed and study designs have been imperfect. The pragmatic position most integrative oncologists take:
The interaction list matters more than the adjunct list. These are the ones that reliably cause trouble in GBM patients.
One of the strongest natural inducers of CYP3A4 and P-glycoprotein. Can significantly lower temozolomide, targeted therapies, and antiseizure drug levels. Common cause of avoidable treatment failure. Avoid entirely.
Inhibits CYP3A4 - the opposite direction from St. John's Wort - and can raise drug levels unpredictably. Applies to several targeted therapies and to the calcium-channel blockers many GBM patients take for blood pressure.
Theoretical interference with the oxidative mechanism of radiation and alkylating chemotherapy. Reintroduce during the maintenance phase if there is a clear reason - otherwise avoid during weeks 1-6.
All can affect bleeding. Stop 7-14 days before craniotomy and any biopsy procedure. Restart after the surgical team clears it.
Many GBM patients are on levetiracetam, valproate, phenytoin, or carbamazepine. Kava, ginkgo, and several traditional herbs can shift their levels and precipitate breakthrough seizures. Any herb should be run past the treating neurologist first.
Concentration, purity, and contamination vary widely. Product testing has repeatedly found undisclosed pharmaceuticals in imported supplements. If you are going to use adjuncts, use audited brands from major manufacturers.
Every adjunct we recommend is filtered through four questions: What does the current tumour biology suggest? What medications are already on board? What phase of treatment are you in - active chemoradiation, maintenance, follow-up, or recurrence? What is your treating oncology team comfortable with?
We do not build stacks for the sake of stacks. A typical adjunctive plan we would propose for a newly-diagnosed MGMT-methylated patient during maintenance TMZ might be: Boswellia for continued oedema management alongside a steroid taper, melatonin at 10-20 mg nightly, an enhanced-absorption curcumin, and a supervised ketogenic strategy monitored via GKI - alongside the standard treatment plan, not instead of it. Everything on that list is defensible with the evidence discussed above.
HBOT sensitises hypoxic tumour to radiation and helps with radiation-necrosis recovery - the adjunct most commonly stacked with the naturals discussed here.
View pageThe metabolic strategy in detail - monitoring, targets, and how it interacts with chemoradiation.
View pageMGMT, IDH, and the wider molecular picture that determines which adjuncts even make sense.
View pageNo. No supplement, herb, or metabolic strategy has been shown to cure glioblastoma. Everything on this page is discussed as adjunctive to, not a replacement for, surgery, radiation, temozolomide, and the rest of your standard treatment plan. Anyone promising a natural cure for GBM is either mistaken or dishonest.
There is meaningful evidence for it. The most-cited study is Kirste et al. (Cancer, 2011), a randomised trial of 44 patients receiving radiotherapy for brain tumours. Roughly 60% of the Boswellia group showed more than 75% reduction in peritumoral oedema on MRI, versus 26% in the placebo group. That does not mean you can drop dexamethasone on your own - it means the discussion is worth having with your neuro-oncologist, particularly if you are trying to taper steroid dose.
The honest answer is: unclear. Preclinical work shows curcumin can sensitise glioma cells to alkylating agents in the dish and in mice, but the human data during active TMZ chemotherapy is limited. Some integrative oncologists pause high-dose curcumin during the concurrent chemoradiation phase and reintroduce it in the maintenance months; others use enhanced-absorption formulations throughout. This is a decision to make with your treating team, not by yourself.
The most reliable list of avoidances: St. John's Wort (induces the enzyme that clears many chemotherapies, including temozolomide and several targeted drugs), grapefruit and grapefruit juice (inhibits the same enzymes and can raise drug levels unpredictably), high-dose vitamin E and N-acetylcysteine during radiation and concurrent chemoradiation (theoretical interference with the oxidative kill mechanism), and any herb your neuro-oncologist has not seen your full medication list first. Many GBM patients take anticonvulsants like levetiracetam or valproate - these have their own interaction profiles.
There is a plausible mechanism (glioma cells rely heavily on glucose; ketones bypass that route), promising preclinical and case-series data, and a growing set of small human trials showing feasibility and safety - but not a large randomised trial proving survival benefit yet. If you want to explore it, do it with medical supervision and monitoring, alongside your standard treatment. Our /gki page covers the mechanism and monitoring in detail.
We look at the specific tumour biology (MGMT status, IDH status, current phase of treatment), the medications you are already on, your current side-effect burden, and what your treating oncology team is comfortable with. We never layer adjuncts blindly. The goal is to support your standard treatment, reduce specific side effects where the evidence is there, and avoid interactions - not to add supplements for the sake of adding them.
No. We do not sell supplements. Our role is to review the evidence with you, discuss the interactions with your treating team, and let you source products from wherever you and your family trust. That independence is part of why we can be honest about the ones that do not work.